Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oleclumab - AstraZeneca

Next Previous
X
Search
Drug Profile

Oleclumab - AstraZeneca

Alternative Names: Anti-CD73 mAb - AstraZeneca; Anti-CD73 monoclonal antibody - AstraZeneca; MEDI-9447

Latest Information Update: 02 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune
  • Developer AstraZeneca; MedImmune
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action 5-nucleotidase inhibitors; Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Breast cancer; Pancreatic cancer; Sarcoma
  • Phase I Solid tumours
  • Discontinued Bladder cancer; Colorectal cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 31 Jul 2024 Discontinued - Phase-I for Bladder cancer (Combination therapy, In the elderly, Neoadjuvant therapy, In adults) in USA (IV) prior to July 2024 (AstraZeneca pipeline, July 2024)
  • 31 Jul 2024 Discontinued - Phase-I/II for Colorectal cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Canada, Spain, Australia, USA (IV) prior to July 2024 (AstraZeneca pipeline, July 2024)
  • 31 Jul 2024 Discontinued - Phase-II for Ovarian cancer (Combination therapy, Second-line therapy or greater) in Finland, Norway, Denmark (IV) prior to July 2024 (AstraZeneca pipeline, July 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top